Patient groups and other stakeholders are invited to comment on a revised procedure for CADTH’s drug reimbursement review processes (that is, the pan-Canadian Oncology Drug Review, the Common Drug Review, and the Interim Plasma Protein Product Review).

To help patient groups and patients contribute to the consultation, this webinar will highlight proposed changes that impact patient groups. Comments shared by patient groups and patients during the webinar will be included as stakeholder feedback.


  • Sarah Berglas, Manager, Patient Engagement, CADTH
  • Trevor Richter, Director, Pharmaceutical Reviews, CADTH
  • Brent Fraser, Vice-President, Pharmaceutical Reviews, CADTH

To participate, please register (there is no cost). After registering, you will receive a confirmation email with information about how to join the webinar. Please note that the webinar will be recorded.

Click here for additional information and registration details.

Related Content

Evidence Matters 2022

Evidence Matters 2022

Evidence Matters is a virtual one-day summit that brings the literature review community together from different industries to learn, engage, and solve ever-pressing evidence-based research challenges.